Ferring, Albireo sign licensing agreement for elobixibat
06:05 EDT 4 Jul 2012 | Pharmaceutical Business Review
Ferring Pharmaceuticals has entered into a licensing agreement with Albireo for elobixibat, a first-in-class compound for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).
Original Article: Ferring, Albireo sign licensing agreement for elobixibat
More From BioPortfolio on "Ferring, Albireo sign licensing agreement for elobixibat"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
